EMH
0.38
58.3%
BP8
0.001
-50%
RDS
0.003
50%
C7A
0.002
-33.3%
PIL
0.004
33.3%
VEE
0.86
-25.5%
CRI
0.029
31.8%
PGY
0.003
-25%
GCM
0.017
30.8%
BLU
0.004
-20%
EPM
0.023
27.8%
BYH
0.004
-20%
CQT
0.049
25.6%
MAUCA
0.905
-17.4%
DTM
0.055
25%
CAV
0.005
-16.7%
H2G
0.01
25%
MAY
0.012
-14.3%
RLG
0.005
25%
G88
0.007
-12.5%
SIS
0.005
25%
GRL
0.014
-12.5%
LKE
0.072
22%
PER
0.007
-12.5%
GT1
0.045
21.6%
M3M
0.029
-12.1%
GW1
0.045
21.6%
PHX
0.145
-12.1%
ICL
0.064
20.8%
LML
0.008
-11.1%
CZN
0.18
20%
PL9
0.008
-11.1%
EGY
0.024
20%
RCR
0.016
-11.1%
PLC
0.006
20%
G11DA
0.29
-10.8%
VAR
0.006
20%
KPO
0.017
-10.5%
STG
0.34
19.3%
PEB
0.13
-10.3%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts